<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03983187</url>
  </required_header>
  <id_info>
    <org_study_id>KY20190530-03</org_study_id>
    <nct_id>NCT03983187</nct_id>
  </id_info>
  <brief_title>Effect of Rotating Magnetic Therapy on Blood Glucose Spectrum of Type 2 Diabetic Patients With Glargine Therapy</brief_title>
  <official_title>Effect of Rotating Magnetic Therapy on Blood Glucose Spectrum of Type 2 Diabetic Patients With Glargine Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Majianhua</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing First Hospital, Nanjing Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess the eï¬€ect of Rotating Magnetic Therapy on blood glucose
      spectrum of type 2 diabetic patients with glargine therapy using flash glucose monitors
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 15, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the standard deviation of blood glucose</measure>
    <time_frame>2 weeks</time_frame>
    <description>the difference of the standard deviation of blood glucose between the two groups assessed by FGM</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>mean blood glucose</measure>
    <time_frame>2 weeks</time_frame>
    <description>mean blood glucose between the two groups assessed by FGM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time in range</measure>
    <time_frame>2 weeks</time_frame>
    <description>time in range assessed by FGM</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Rotating Magnetic Therapy group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Rotating Magnetic Therapy</intervention_name>
    <description>Rotating Magnetic Therapy 30min/ Bid for 1 month</description>
    <arm_group_label>Rotating Magnetic Therapy group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Volunteer to participate and sign informed consent prior to the study

          -  Patients with type 2 diabetes, who met WHO1999 diagnostic criteria, aged 18-70 years
             old, and were treated with insulin glargine alone and/or insulin glargine combined
             with oral hypoglycemic drugs, the treatment regimen was stable for more than 2 months

          -  Fasting blood glucose ranged from 6.1 to 13.9mmolL, and postprandial (or random) blood
             glucose was &lt;22.2mmol/L.

          -  Subjects can and are willing to conduct flash glucose monitoring and regular diet and
             exercise

        Exclusion Criteria:

          -  Patients with insulin allergy

          -  Patients treated with GLP-1a or DPP-4 inhibitors or multipoint subcutaneous insulin
             injection in the last three months

          -  Impaired liver and kidney function with ALT 2.5 times higher than the upper limit of
             normal value and serum creatinine 1.3 times higher than the upper limit of normal
             value

          -  Patients with metal foreign bodies or pacemakers

          -  Patients with a history of surgery in magnetic therapy site within one year

          -  Patients with obvious discomfort to magnetic therapy

          -  Patients with bleeding or bleeding tendency

          -  Patients with poor compliance and irregular diet and exercise

          -  Patients with acute complications of diabetes, such as infection, diabetic
             ketoacidosis, hypertonic coma and so on, and patients with stress status within four
             weeks

          -  Patients who are pregnant, breast-feeding, or intending to become pregnant

          -  Any other apparent conditions or associated diseases determined by the investigator:
             severe cardiopulmonary, endocrine, neurological, tumor, other pancreatic diseases,
             history of mental illness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 10, 2019</study_first_submitted>
  <study_first_submitted_qc>June 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2019</study_first_posted>
  <last_update_submitted>June 13, 2019</last_update_submitted>
  <last_update_submitted_qc>June 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Nanjing First Hospital, Nanjing Medical University</investigator_affiliation>
    <investigator_full_name>Majianhua</investigator_full_name>
    <investigator_title>Director, Head of Endocrinology department, Clinical Professor</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

